Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Carine A. Bellera, N. Penel, M. Ouali, S. Bonvalot, P. G. Casalli, O. S. Nielsen, M. Delannes, S. Litière, F. Bonnetain, T. S. Dabakuyo, R. Benjamin, J. Y. Blay, B. N. Bui, F. Collin, T. F. Delaney, F. Duffaud, T. Filleron, M. Fiore, H. Gelderblom, S. GeorgeR. Grimer, P. Grosclaude, A. Gronchi, R. Haas, P. Hohenberger, R. Issels, A. Italiano, V. Jooste, A. Krarup-Hansen, C. Le Péchoux, C. Mussi, O. Oberlin, S. Patel, S. Piperno-Neumann, C. Raut, I. Ray-Coquard, P. Rutkowski, S. Schuetze, S. Sleijder, E. Stoeckle, M. Van Glabbeke, P. Woll, S. Gourgou-Bourgade, S. Mathoulin-Pélissier

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)'. Together they form a unique fingerprint.

Medicine & Life Sciences